



# IdaHealth Showcases Technology to Standardize Radial Occlusion Artery Monitoring at EuroPCR 2019

PARIS, May 23, 2019 – IdaHealth, a medical device company dedicated to modernizing proactive patient care through innovative monitoring systems, today introduced the company’s radial occlusion artery monitoring (ROAM) technology, IdaFlo Tr, during a presentation at the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) in Paris. IdaFlo Tr is an innovative transradial nanotechnology-based bracelet that allows for the continuous, real-time and wireless monitoring of radial arterial blood flow.

The presentation “Moving from a Blind to a Controlled Post-PCI Compression in Order to Avoid Radial Artery Occlusion Using a New Wireless Real-Time Flow Monitor Technology We Call Radial Occlusion Artery Monitor,” was led by Dr. Giovanni Amoroso, an interventional cardiologist and expert in transradial coronary procedures from Amsterdam, Netherlands. Within the presentation, Dr. Amoroso highlighted the unmet need of a standardized post-percutaneous coronary intervention (PCI) procedure to avoid a radial artery occlusion (RAO). Implementing IdaFlo Tr provides considerable advantages in pre’, peri’ and post-PCI, including:

- RAO screening pre-PCI
- Predictive detection of radial artery occlusion post-PCI and prevention of occlusions by pressure adaptation based on blood flow measurement
- Workload reduction for the doctors and nurses
- Cost savings by preventing RAO

[Get in Touch](#)

## Key Takeaways

- Preliminary results presented by Dr. Giovanni Amoroso during the NewSolutions for Serious Needs session of EuroPCR
- IdaFlo Tr has the potential to standardize transradial angioplasty monitoring. It adds eyes to a blind procedure
- IdaFlo Tr has the potential to decrease the incidence of RAO, increase safety of transradial angioplasty PCI procedures and reduce workload for physicians and nurses

[See presentation](#)

## Images



[Preview](#) [Download](#)



Cost savings by preventing RAO

A recent proof of concept study, also summarized at EuroPCR, was conducted using prototypes of IdaFlo Tr on three coronary catheterization patients in Amsterdam. The results confirmed that IdaFlo Tr can detect abnormal blood flow after a coronary catheterization procedure, allowing a clinician to adjust the compression device that is commonly used to close the puncture site in the recovery room and, therefore, prevent occlusions.

“The advantages of IdaFlo Tr are remarkable. It adds eyes to a blind procedure,” said Dr. Amoroso. “Preliminary results confirm proof of concept and the value IdaFlo Tr may provide to physicians, nurses and patients. IdaFlo Tr has the potential to standardize transradial angioplasty monitoring.”

IdaFlo Tr supports AI self-learning and telemedicine capabilities and is protected by a first provisional patent that defines the use of nanofiber technology in blood flow monitoring with extreme precision, continuous and real-time wireless monitoring via an iPad tablet and application.

“With lower all-cause mortality, vascular complications and major bleeding events, transradial access in PCI has become a prevalent method for interventional cardiologist,” said David Camp, President, CEO and Co-founder of IdaHealth and General Manager of MACCO International Limited consulting firm. “RAO is the most common vascular complication of the transradial approach and there is no standard of care to minimize the incidence of RAO. IdaFlo Tr has the potential to decrease the incidence of RAO, increase safety of transradial angioplasty PCI procedures and reduce workload for physicians and nurses.”

**About IdaHealth**

IdaHealth is a medical device company that designs, manufactures and markets non invasive disruptive predictive monitoring solutions that provide continuous information to proactively improve quality of life.

It is IdaHealth’s vision to becoming the leader of creating and delivering disruptive solutions that change the standard of care for non invasive and predictive monitoring systems to enhance quality of life. Using IdaHealth’s patented technology, the company is developing its first two breakthrough products.

**IdaHealth delivers solutions that simply do not exist today.**



Preview Download

Files

IdaHealth presentation at EuroPCR 2019  
Download

Quotes

“**IdaFlo Tr has the potential to decrease the incidence of RAO, increase safety of transradial angioplasty PCI procedures and reduce workload for phy...**  
David L. Camp Jr – President & CEO

“**The advantages of IdaFlo Tr are remarkable. It adds eyes to a blind procedure**  
Dr Giovanni Amoroso, MD, PhD – Interventional Cardiologist

Related Bios

**David L. Camp Jr**  
President & CEO • Co-founder  
View full bio >>

**Giovanni Amoroso**  
Medical Advisor  
View full bio >>

Contacts

David Camp Jr  
[david@idahealth.com](mailto:david@idahealth.com)  
+1 (954) 806-2962